This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

Bioprinting 3D 2018 - 2028 : Technologies, Marchés, Prévisions

Possibilités dans le domaine des cosmétiques et des tests de produits de consommation, de développement de médicaments et de médecine régénératrice

Show All Description Contents, Table & Figures List Pricing Related Content
Interest in 3D bioprinting has been gaining momentum in recent years, both in the academic and commercial settings. Between 2014 and 2015, the market welcomed numerous 3D bioprinting companies, and new start-ups, spin-outs, and subsidiaries are continuing to emerge. Though investment in the field has been driven on by the futuristic goal of providing solutions for regenerative by way of fabricating organs for transplant, more realistic applications in product development and testing have shown great promise and are already being marketed. Over 2016, several 3D bioprinting companies saw a doubling of revenue, and comparable results are anticipated for the next few years. Given these market trends, IDTechEx forecasts that the global market for 3D bioprinting will reach a value of $1.9 billion by the year 2028.
Technology and Applications
3D bioprinting can be defined in a variety of ways, and each definition includes and excludes large swathes of key biotechnology markets. In this report, IDTechEx has defined 3D bioprinting as the deposition of living cells in a spatially controlled manner in the absence of any pre-existing scaffold and in more than a single layer. Under this definition, 3D bioprinters are currently based on four main printhead technologies:
  • Inkjet
  • Extrusion
  • Laser-induced forward transfer
  • Microvalve
This report profiles each technology and its subtypes, and provides key specifications, vendors, and SWOT analyses. This report also introduces and discusses 3D bioprinting technologies of microfluidic chip, microneedle array, 2-photon polymerization, and cell electrospinning amongst others. Technologies and considerations relevant to the 3D bioprinting process, such as software, bioink (including cell selection, growth factors, and scaffold materials), and post-printing maturation are also discussed.
Current and future applications for 3D bioprinting discussed in this report include:
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalised medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Education
  • Academic research
  • Bionics
Regenerative Medicine
Special attention is paid to regenerative medicine in this report, as not only does it have the potential to be the largest application for 3D bioprinting in the future, but also one with the highest impact. This report analyses how 3D bioprinting can be applied to regenerative medicine, and focuses on the following tissue types:
  • Bone and cartilage
  • Skin
  • Dental
  • Vasculature
  • Complex organs
Additionally, discussion of current progress in bringing 3D bioprinted tissues to the clinic is provided, as well future hurdles to be faced. A roadmap of 3D bioprinting in regenerative medicine to the year 2050 is provided.
This report forecasts the overall 3D bioprinting market to 2028, with in depth discussion of key trends in the short term (2018 - 2022), and those expected in the long term (2023 - 2028). Market forecasts to 2028 are also provided for the 3D bioprinter market segmented by price point, and the 3D bioprinted tissue market segmented by tissue application.
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at or call one of our sales managers:

AMERICAS (USA): +1 617 577 7890
ASIA (Japan): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
Table of Contents
1.2.Key 3D Bioprinter Manufacturers
1.3.3D Bioprinting Service Bureaus
1.4.High Profile Partnerships
1.5.3D Bioprinter Market Forecast 2018 - 2028
1.6.3D Bioprinted Tissue Market Forecast 2018 - 2028
1.7.Key Drivers
1.8.Key Challenges
2.1.Report Scope / 3D Bioprinting Definition
2.2.3D Bioprinting Process
2.3.3D Bioprinting Process: Discussion
2.4.3D Cell Culture Advantages
2.5.3D Bioprinting Advantages
2.6.Key Driver: Regenerative Medicine
2.7.Key Driver: Unmet Need in Organs for Transplant
2.8.Key Driver: Product Testing in Medicine
2.9.Key Driver: Avoiding Costly Drug Trial Failures
2.10.Key Driver: Product Testing in Consumer Products
2.11.Major Bioprinting Firsts
2.12.Key Trends: 3D Bioprinters
2.13.Key Trends: Bioprinted Tissues
2.14.Key Competing Technologies
2.15.Current Biological Challenges
2.16.Regulatory Hurdles
2.17.3D Bioprinting SWOT Analysis
3.1.From 3D Printing to 3D Bioprinting
3.2.3D Bioprinting Technologies
3.3.Comparison of Key Specifications
3.4.3D Bioprinting Technology Comparison
3.5.Inkjet: Introduction
3.6.Inkjet: Key Specifications
3.7.Inkjet: Thermal
3.8.Inkjet: Piezoelectric
3.9.Inkjet: Advantages
3.10.Inkjet: Challenges
3.11.Inkjet: SWOT Analysis
3.12.Extrusion: Introduction
3.13.Extrusion: Key Specifications
3.14.Extrusion: Pneumatic
3.15.Extrusion: Mechanical
3.16.Extrusion: Advantages
3.17.Extrusion: Challenges
3.18.Extrusion: SWOT Analysis
3.19.Laser: Introduction
3.20.LIFT: Key Specifications
3.21.LIFT: Laser-Induced Forward Transfer
3.22.LIFT: Advantages
3.23.LIFT: Challenges
3.24.LIFT: SWOT Analysis
3.25.Microvalve: Introduction
3.26.Microvalve: Key Specifications
3.27.Microvalve: Solenoid
3.28.Microvalve: Advantages
3.29.Microvalve: Challenges
3.30.Microvalve: SWOT Analysis
3.31.Other Technologies
3.32.Microfluidic Chip
3.33.In-Air Microfluidics
3.35.Microneedle Array
3.36.2-Photon Polymerization
3.37.Cell Electrospinning
3.38.Microscale Continuous Optical Bioprinting
3.39.Paramagnetic and Acoustic
3.40.Industry-wide Technical Challenges
3.41.The Ideal 3D Bioprinter
3.42.Future Technological Directions
4.1.Related Technologies
4.2.3D Bioprinting Software
4.3.Bioink Preparation
4.4.Cell Selection
4.5.Cell Selection: Regenerative Medicine
4.6.Cell Selection: Bacteria
4.7.Growth Factors and Other Additives
4.8.Matrix Materials
4.9.Matrix Materials: Companies
4.10.The Ideal Scaffold Material
4.11.Cell Spheroid Printing
5.2.Testing of Cosmetics and Other Consumer Goods
5.3.Testing of Cosmetics and Other Consumer Goods: Skin
5.4.Drug Screening
5.5.Drug Screening: Drug Development Process
5.6.Drug Screening: Benefits of 3D Bioprinting
5.7.Drug Screening: Cancer
5.8.Personalised Medicine
5.9.Regenerative Medicine
5.10.Regenerative Medicine: Tissue Roadmap
5.11.Regenerative Medicine: Bone and cartilage
5.12.Regenerative Medicine: Skin
5.13.Regenerative Medicine: Dental
5.14.Regenerative Medicine: Vasculature
5.15.Regenerative Medicine: Complex Organs
5.16.Regenerative Medicine: Mini-Organs
5.17.Cell-Based Biosensors
5.18.Food and Other Animal Products
5.20.Academic Research
6.2.Growing 3D Bioprinting Market
6.3.Key 3D Bioprinter Manufacturers
6.4.3D Bioprinting Service Bureaus
6.5.High Profile Partnerships
6.6.Research Groups and Centers
6.7.Market Barriers
6.8.Key Losers
6.10.Overall 3D Bioprinting Market Forecast 2018 - 2028
6.11.Overall 3D Bioprinting Market Forecast: Short and Long Term
6.12.3D Bioprinting Value Chain
6.13.3D Bioprinting Value Chain: Discussion
6.14.3D Bioprinter Manufacturers
6.15.3D Bioprinters by Cost and Technology
6.16.3D Bioprinter Market Forecast 2018 - 2028
6.17.3D Bioprinter Market Forecast: Short Term
6.18.3D Bioprinter Market Forecast: Long Term
6.19.3D Bioprinted Tissue Forecast 2018 - 2028
6.20.3D Bioprinted Tissue Forecast: Consumer Products
6.21.3D Bioprinted Tissue Forecast: Pharmaceuticals
6.22.3D Bioprinted Tissue Forecast: Others
7.2.Regulatory Hurdles
7.3.Regenerative Medicine Advanced Therapy Designation
7.4.RMAT: 1 year Later
7.6.Scams and Schemes
7.7.From Lab to Clinic
7.8.3D Bioprinting Roadmap to 2050
8.1.List of Abbreviations
8.2.List of 3D Bioprinting Companies
9.1.3D Bioprinting Solutions/Vivax Bio
9.2.3Dynamic Systems
9.4.Aspect Biosystems
9.5.BioBots (now Allevi)
9.6.BioDan Group
9.13.Microdrop Technologies
9.14.MicroFab Technologies
9.18.Prellis Biologics
9.19.Regemat 3D
9.22.Sichuan Revotek

Report Statistics

Slides 225
Companies 21
Forecasts to 2028

Subscription Enquiry